Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2025-06-09 00:00:00 ET · period of report 2025-06-09 · accession 0001628280-25-030306 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-06-09 | 2025-06-09 | VIR | MORE ROBERT J | Dir | J - Other | $0.00 | +14.0K | 509.9K | +3% | $0 |
| 2025-06-09 | 2025-06-09 | VIR | MORE ROBERT J | Dir | J - Other | $0.00 | -14.0K | 40.7K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-09 | J | A | 14,027 | $0.00 | 509,917 | I | — | — | |
| 2 | Common | Common Stock | 2025-06-09 | J | D | 14,027 | $0.00 | 40,656 | D See footnote | — | — | (F2) The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |